Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Vaylen vs Alan Meds

Both scored on the same six-factor Match Score. Vaylen wins this matchup with a 87 to 86 edge — a photo finish.

Higher Match Score

Vaylen

#5 · Grade B+

People who want maximum options — injectable, oral, compounded or brand — in one LegitScript-certified place.

Visit Vaylen
VS

Alan Meds

#7 · Grade B+

Budget shoppers who want an oral/sublingual route without giving up nationwide access.

Visit Alan Meds

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
82
93
Speed to Start
88
88
Formulary Match
94
86
Support Level
86
82
Flexibility
86
84
Transparency
88
80

Price, coverage & formulary

DetailVaylenAlan Meds
Semaglutide$179/mo$99/mo
Tirzepatide$239/mo$145/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Match Score87 · B+86 · B+
Winner: Vaylen

Vaylen edges out Alan Meds, 87 to 86 on the default Match Score. One of the widest formularies on the board — both molecules, an oral route, and brand access, all nationwide.

Alan Meds is still a fair pick if its strengths line up with yours — best for: Budget shoppers who want an oral/sublingual route without giving up nationwide access.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Vaylen reviewFull Alan Meds review

More head-to-heads

Or browse alternatives to Vaylen and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.